---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-114055"
form_type: "8-K"
ticker: null
cik: "0000786947"
company_name: "ACURA PHARMACEUTICALS, INC"
filed_at: "2026-10-06T20:16:16+00:00"
generated_at: "2026-10-12T16:17:51.168014+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Acura Pharmaceuticals borrows $200,000 from Abuse Deterrent Pharma; note principal reaches $11,294,279

## Summary
- Acura received $100,000 loans from Abuse Deterrent Pharma on Sept 18 and Oct 2, 2026, raising the secured note principal to $11,294,279.
- Accrued interest was about $1,365,000 as of Sept 30, 2026; the note bears 5.25%, with overdue amounts at 7.5%.
- Absent additional financing by mid-October 2026, Acura says it may scale back operations, furlough or lay off employees, terminate operations, or seek bankruptcy protection.
- Events of default include failure to pay principal or interest continuing 5 days, bankruptcy events, and inability to pay debts as they come due.
- Exhibit 99.1 lists Loans #51 through #66, including Loan #66 dated Oct 2, 2026 for $100,000.

## SEC filing metadata
- accession: 0001104659-26-114055
- form_type: 8-K
- cik: 0000786947
- company_name: ACURA PHARMACEUTICALS, INC
- filed_at: 2026-10-06T20:16:16+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/786947/000110465926114055/0001104659-26-114055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/786947/000110465926114055/tm2627130d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-114055
- JSON: https://secwatch.observer/filing/0001104659-26-114055.json
- Plain text: https://secwatch.observer/filing/0001104659-26-114055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.